{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:59:46Z","timestamp":1761490786156,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12325-019-00938-1","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T16:35:47Z","timestamp":1554741347000},"page":"1252-1265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson\u2019s Disease: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Hongxin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Refoios Camejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiajun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-514X","authenticated-orcid":false,"given":"Daniel","family":"Parks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"938_CR1","doi-asserted-by":"crossref","unstructured":"Poewe W. Parkinson disease. Nature Reviews Disease Primers. 2017;3:Article number: 17013","DOI":"10.1038\/nrdp.2017.13"},{"issue":"24","key":"938_CR2","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498\u2013508.","journal-title":"N Engl J Med"},{"key":"938_CR3","doi-asserted-by":"crossref","unstructured":"Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010(7):CD007166.","DOI":"10.1002\/14651858.CD007166.pub2"},{"issue":"1","key":"938_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/0023210-200923010-00006","volume":"23","author":"J Weber","year":"2009","unstructured":"Weber J, Keating GM. Ropinirole prolonged release: in advanced Parkinson's disease. CNS Drugs. 2009;23(1):81\u201390.","journal-title":"CNS Drugs"},{"issue":"14","key":"938_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108\u201315.","journal-title":"Neurology"},{"issue":"4","key":"938_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","volume":"66","author":"MM Pinter","year":"1999","unstructured":"Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66(4):436\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"938_CR7","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: NICE Decision Support Unit Technical Support Documents; 2014."},{"issue":"5","key":"938_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33(5):618\u201340.","journal-title":"Med Decis Making"},{"key":"938_CR9","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Inconsistency in networks of evidence based on randomised controlled trials. London: NICE Decision Support Unit Technical Support Documents; 2014."},{"issue":"6","key":"938_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320.","journal-title":"Lancet Neurol"},{"issue":"3","key":"938_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1046\/j.1468-1331.1998.530235.x","volume":"5","author":"L Wermuth","year":"1998","unstructured":"Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol. 1998;5(3):235\u201342.","journal-title":"Eur J Neurol"},{"issue":"5","key":"938_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/mds.20397","volume":"20","author":"JC Moller","year":"2005","unstructured":"Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005;20(5):602\u201310.","journal-title":"Mov Disord"},{"issue":"8","key":"938_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77(8):767\u201374.","journal-title":"Neurology"},{"issue":"1","key":"938_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0022-510X(03)00217-X","volume":"216","author":"KS Wong","year":"2003","unstructured":"Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci. 2003;216(1):81\u20137.","journal-title":"J Neurol Sci"},{"issue":"1","key":"938_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.49.1.162","volume":"49","author":"A Lieberman","year":"1997","unstructured":"Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162\u20138.","journal-title":"Neurology"},{"issue":"4","key":"938_CR16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","volume":"49","author":"M Guttman","year":"1997","unstructured":"Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997;49(4):1060\u20135.","journal-title":"Neurology"},{"issue":"3","key":"938_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","volume":"19","author":"O Rascol","year":"1996","unstructured":"Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 1996;19(3):234\u201345.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"938_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","volume":"51","author":"A Lieberman","year":"1998","unstructured":"Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology. 1998;51(4):1057\u201362.","journal-title":"Neurology"},{"key":"938_CR19","unstructured":"Korczyn. Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole versus placebo as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa. Confidential Report. 1990."},{"issue":"7","key":"938_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord. 2011;26(7):1259\u201365.","journal-title":"Mov Disord"},{"issue":"10","key":"938_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/mds.10508","volume":"18","author":"Y Mizuno","year":"2003","unstructured":"Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord. 2003;18(10):1149\u201356.","journal-title":"Mov Disord"},{"key":"938_CR22","doi-asserted-by":"publisher","unstructured":"Hattori N, Nishioka H, Hasegawa K. Comparison of ropinirole controlled- and immediate-release in Japanese patients with advanced Parkinson's disease. Neurol Clin Neurosci. 2015;3(1):18\u201324. \n                    https:\/\/doi.org\/10.1111\/ncn3.128\n                    \n                  .","DOI":"10.1111\/ncn3.128"},{"issue":"1","key":"938_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/nmt-2016-0038","volume":"7","author":"TA Zesiewicz","year":"2017","unstructured":"Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, Davy M, VanMeter S. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease. Neurodegener Dis Manag. 2017;7(1):61\u201372.","journal-title":"Neurodegener Dis Manag"},{"issue":"4","key":"938_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e31825f77b9","volume":"35","author":"Y Mizuno","year":"2012","unstructured":"Mizuno Y, Yamamoto M, Kuno S, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35(4):174\u201381.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"938_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.parkreldis.2014.10.005","volume":"20","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Nomoto M, Hasegawa K, et al. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. Parkinsonism Relat Disord. 2014;20(12):1388\u201393.","journal-title":"Parkinsonism Relat Disord"},{"key":"938_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2047-9158-3-11","volume":"3","author":"Y Wang","year":"2014","unstructured":"Wang Y, Sun S, Zhu S, et al. The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study. Transl Neurodegener. 2014;3:11.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"938_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.parkreldis.2013.07.009","volume":"19","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Wang J, Zhang X, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 2013;19(11):1022\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"13","key":"938_CR28","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/mds.21313","volume":"22","author":"Y Mizuno","year":"2007","unstructured":"Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov Disord. 2007;22(13):1860\u20135.","journal-title":"Mov Disord"},{"issue":"4","key":"938_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/pst.491","volume":"10","author":"JW Stevens","year":"2011","unstructured":"Stevens JW. A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS. Pharm Stat. 2011;10(4):374\u20138.","journal-title":"Pharm Stat"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00938-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00938-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00938-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:16:30Z","timestamp":1586214990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00938-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00938-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}